Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 16, 2020Cancer Treatment ReviewsOpen Access

MEK inhibitor resistance mechanisms and recent developments in combination trials

View Full Paper
Ask AI
Bookmark
Share

Authors

EKEucharist KunThe University of Texas at AustinYTYvonne T.M. TsangThe University of Texas MD Anderson Cancer CenterCNChun Wai NgThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kun et al. (2020) studied this question.

synapsesocial.com/papers/6aa8aca372f784a6546bf8dehttps://doi.org/10.1016/j.ctrv.2020.102137
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells2018 · 164 citations
  2. 2MEK1 mutations confer resistance to MEK and B-RAF inhibition2009 · 642 citations